NCT04758455 is a NA clinical trial of P53, Ki67 and Cyclin A IHC. in Wilms Tumor, sponsored by Mansoura University.

Who is sponsoring NCT04758455?

NCT04758455 is sponsored by Mansoura University.

What drugs are being tested in NCT04758455?

Interventions in NCT04758455: P53, Ki67 and Cyclin A IHC..

What condition does NCT04758455 study?

NCT04758455 studies Wilms Tumor, Relapse, Death.

Is NCT04758455 still recruiting?

NCT04758455 is currently status unknown. Last updated 16 February 2021.

Last reviewed 2021-02-16 · How we verify

NCT04758455

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

P53, Ki67 and Cyclin A Immunohistochemical Staining as Predictors for Wilms' Tumour Aggressiveness and Recurrence

Status unknown NA Last updated 16 February 2021

What this trial tests

NA trial testing P53, Ki67 and Cyclin A IHC. in Wilms Tumor in 75 participants. Status unknown.

Timeline

14 February 2021

Primary endpoint
1 March 2021

1 April 2021

Quick facts

Lead sponsor	Mansoura University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	single
Primary purpose	diagnostic
Enrollment	75
Start date	14 February 2021
Primary completion	1 March 2021
Estimated completion	1 April 2021
Sites	1 location across Egypt

Drugs / interventions tested

P53, Ki67 and Cyclin A IHC.

Conditions studied

Wilms Tumor — all drugs for Wilms Tumor →
Relapse — all drugs for Relapse →
Death — all drugs for Death →

Sponsor

Mansoura University

Who can join

Under 18, any sex, with Wilms Tumor or Relapse. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To test the ability of P53, Ki67 and cyclin A to predict Wilms' tumour recurrence and progression.
Time frame: 2 months
By correlating P53, Ki67 and cyclin A IHC to tumor stage, histopathology and patients' follow-up.

Sponsor's own description

Wilms' tumour staging and grading are used to give an idea about the prognosis. Advanced staging, diffuse anaplasia, predominant blastemal elements and lymph node invasion are indicators of poor prognosis. In spite of using the previously mentioned parameters, some tumours which were considered of low risk did not respond to therapy and eventually resulted in mortality. In contrast, other tumours assumed to be of poor prognosis responded dramatically to treatment. In light of the above, it is crucial to search for predictors of Wilms' tumour prognosis other than tumour staging and grading. Many immunohistochemical (IHC) stains have been studied as prognostic markers for nephroblastoma in literature.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Does immunohistochemical staining of P53, Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival?
Atwa AM, Hafez AT, Abdelhameed M, Dawaba M, et al · · 2022 · cited 3× · PMID 35935912 · DOI 10.1080/2090598x.2022.2058240

Verify or expand the search:

Other recruiting trials for Wilms Tumor

Currently open trials in the same condition.

NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
NCT06198296 — Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells · Phase 1 · recruiting
NCT04715191 — Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tu · Phase 1 · recruiting
NCT05985161 — A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors · Phase 2 · recruiting
NCT04897321 — B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) · Phase 1 · recruiting

Other Mansoura University trials

Trials by the same sponsor.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04758455 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mansoura University
Last refreshed: 16 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04758455.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing